Investment firm Hillhouse led a $147m Series D round in InventisBio, a clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, with participation from Qiming Venture Partners, Janchor, AIHC Capital, Matrix Partner China, Dyee Capital and E Fund Capital. The existing shareholders including Lilly Asia Venture, OrbiMed Asia, Pudong Innotek, AdvanTech Capital, and CMB International continued their support. "InventisBio is committed to developing first- and best-in-class innovative drugs for cancer and other major diseases. We are grateful and honored to have Hillhouse's GL Ventures led this series D round and thankful to other top investment funds, as well as the continued support from the existing investors. This investment demonstrated the recognition of our strong pipeline and fully integrated innovative R&D platform by top healthcare investors. It also shows our strategic investors' confidence in the future success of our company as a key player in the global pharmaceutical market," Yaolin Wang, InventisBio Chairman and CEO.